Immune Modulation of Allergic Asthma by Early Pharmacological Inhibition of RIP2

Madelyn H. Miller, Michael G. Shehat and Justine T. Tigno-Aranjuez

*Immu*noHorizons 2020, 4 (12) 825-836
doi: https://doi.org/10.4049/immunohorizons.2000073
http://www.immunohorizons.org/content/4/12/825

This information is current as of March 24, 2021.

**Supplementary Material**
http://www.immunohorizons.org/content/suppl/2020/12/18/4.12.825.DCSupplemental

**References**
This article cites 47 articles, 11 of which you can access for free at:
http://www.immunohorizons.org/content/4/12/825.full#ref-list-1

**Email Alerts**
Receive free email-alerts when new articles cite this article. Sign up at:
http://www.immunohorizons.org/alerts
Immune Modulation of Allergic Asthma by Early Pharmacological Inhibition of RIP2

Madelyn H. Miller, Michael G. Shehat, and Justine T. Tigno-Aranjuez
Immunity and Pathogenesis Division, Burnett School of Biomedical Sciences, University of Central Florida College of Medicine, Orlando, FL 32827

ABSTRACT
Exposure to house dust mite (HDM) is highly associated with the development of allergic asthma. The adaptive immune response to HDM is largely Th2 and Th17 dominant, and a number of innate immune receptors have been identified that recognize HDM to initiate these responses. Nucleotide-binding oligomerization domain-containing protein 2 (NOD2) is a cytosolic sensor of peptidoglycan, which is important for Th2 and Th17 polarization. NOD2 mediates its signaling through its downstream effector kinase, receptor-interacting serine/threonine protein kinase 2 (RIP2). We have previously shown that RIP2 promotes HDM-associated allergic airway inflammation and Th2 and Th17 immunity, acting early in the HDM response and likely within airway epithelial cells. However, the consequences of inhibiting RIP2 during this critical period has not yet been examined. In this study, we pharmacologically inhibited RIP2 activity during the initial exposure to allergen in an acute HDM model of asthma and determined the effect on the subsequent development of allergic airway disease. We show that early inhibition of RIP2 was sufficient to reduce lung histopathology and local airway inflammation while reducing the Th2 immune response. Using a chronic HDM asthma model, we demonstrate that inhibition of RIP2, despite attenuating airway inflammation and airway remodeling, was insufficient to reduce airway hyperresponsiveness. These data demonstrate the potential of pharmacological targeting of this kinase in asthma and support further development and optimization of RIP2-targeted therapies.

INTRODUCTION
Asthma is a chronic inflammatory disease of the airways that affects up to 300 million people worldwide (1). It is characterized by narrowing of the airways, mucus overproduction, airway hyperresponsiveness (AHR), and pathological airway remodeling. Two endotypes (subgroups with similar pathophysiology) are generally recognized for asthma: type 2 (or type 2 high) and non–type 2 (or type 2 low) (2). Around half of all asthmatics have type 2 inflammation, and of these, the majority suffer from allergic asthma (3). Exposure and sensitization to indoor allergens such as pet dander, cockroaches, and dust mites are consistently associated with the development of allergic asthma (4–6). Of these aeroallergens, house dust mites (HDM) are the most frequent sensitizer, with up to 70% of asthmatics showing reactivity to this allergen (7–11).
Type 2 or Th2 immunity is distinguished by elevated production of the canonical type 2 cytokines IL-4, IL-5, and IL-13 (12). In the pathologic setting of allergic asthma, these cytokines are critical mediators that collectively result in the observed asthmatic symptoms. The large number of therapeutics developed to target these type 2 cytokines and their receptors or type 2–induced IgE and IgE receptors, as well as clinical translation of such biologics, reflect their importance in the progression of type 2 disease (13). However, the limited indication for such biologics (type 2 asthmatics who have severe disease or high eosinophil counts) as well as the high cost and need for chronic administration point to the need for novel therapeutic targets that lie upstream of type 2 cytokine production and that have the potential to modulate the type 2 response.

Initiation of type 2 immunity in response to HDM is a process orchestrated by multiple cell types, including epithelial cells, dendritic cells (DCs), group 2 innate lymphoid cells (ILC2s), mast cells, and basophils (12). Likewise, numerous receptors and pathways in innate and structural cells have been implicated in the initial recognition and response to HDM (14). Using knockout (KO) models, our own laboratory has previously demonstrated that receptor-interacting serine/threonine protein kinase 2 (RIP2) is involved in promoting allergic airway inflammation in response to HDM (15). Importantly, multiple lines of evidence, including HDM-induced activation of RIP2 within airway epithelial cells, suggested that the actions of RIP2 were crucial at a very early time point. RIP2 is a kinase that mediates signaling downstream of nucleotide-binding oligomerization domain-containing protein 2 (NOD2), a cytosolic receptor for bacterial peptidoglycan (16, 17). Apart from allergic airway inflammation, RIP2 has also been associated with the pathogenesis of various inflammatory diseases, including inflammatory bowel disease, arthritis, and experimental autoimmune encephalomyelitis (18–20). These findings have spurred the development and preclinical testing of numerous RIP2 inhibitors as well as initiation of a Phase I clinical trial (21).

In the current work, we examine the efficacy of early and acute pharmacological inhibition of RIP2 in the setting of an HDM-induced allergic asthma model. The resulting findings may lend further support for RIP2 as being a viable druggable target in the setting of allergic asthma.

**MATERIALS AND METHODS**

**Mice**

C57BL/6J mice (000664) were obtained from The Jackson Laboratory (Bar Harbor, ME) and were housed in specific pathogen-free and American Association of Laboratory Animal Care–accredited animal facility at the University of Central Florida (UCF) Health Science Campus at Lake Nona. Eight-week-old male and female mice were used for the experiments. All animal procedures were performed in accordance with the guidelines of the Institutional Animal Care and Use Committee of the UCF and using a reviewed and approved animal protocol.

**HDM asthma models and pharmacological RIP2 inhibition GlaxoSmithKline intervention**

Lyophilized *Dermatophagoides pteronyssinus* (HDM) was obtained from Greer Laboratories (XPB82D3A2.5, Lot no. 346230) (Lenoir, NC), resuspended in sterile PBS at necessary concentrations, and frozen in aliquots at −20°C until use. For all models, irradiated GSK583 chow (0.25 g GSK583/kg chow, C19062701i; Research Diets, New Brunswick, NJ) or irradiated vehicle chow (C18513i; Research Diets) was provided ad libitum on days −2 to 2 day. This amount will deliver ~30 mg/kg/d based on a 3 g/d consumption per mouse. On day 3, all mice were switched to vehicle chow.

The acute HDM model was conducted as previously published (15). On day 0, 40 μl of a 1.5 mg/ml HDM mixture was delivered intratracheally (i.t.), whereas 25 μl of a 0.5 mg/ml HDM mixture was delivered i.t. from days 7 to 11. For the chronic HDM model, mice were additionally administered 25 μl of a 0.5 mg/ml HDM mixture on days 14, 16, 18, 21, 23, and 25. All intratracheal instillations of HDM were performed using an endotracheal instillation kit with animals under isoflurane anesthesia.

Mice were euthanized on day 14 or day 28 (depending on the model) for collection of tissues. Depending on the experiment and model duration, the following tissues were collected: bronchoalveolar lavage (BAL) and lung for analysis of infiltrating immune subsets, blood for serum analysis, lung for measurement of local cytokines, lung for analysis of Th subsets, and lung for histological assessment.

**Histopathological scoring**

Lung tissue was harvested from euthanized mice for histology. Tissue was fixed in 10% buffered formalin and sent to AML Laboratories (St. Augustine, FL) for paraffin embedding, sectioning, and H&E, periodic acid–Schiff (PAS), and Masson trichrome staining to assess total inflammation, mucus production, and collagen deposition/fibrosis, respectively. All sections were scored blindly using a modified histopathological scoring system as previously published (15, 22). Bronchoarterial inflammation, pulmonary vein inflammation, amuscular blood vessel inflammation, interalveolar space inflammation, and pleural inflammation were combined into one inflammatory index with a maximum score of 16. The maximum score for mucus production was 4, and the maximum score for trichrome staining was 6 (the maximum score being the most severe). For the chronic model, an alternative scoring system to assess chronic airway remodeling was used, for a maximum combined score of 22. The following parameters were assessed for prevalence throughout the section: epithelial folding/distortion (0–2), goblet cell metaplasia (0–2), smooth muscle cell hypertrophy (0–2), subepithelial fibrosis (0–2), peribronchial trichrome blue staining (0–3), and parenchymal collagen deposition (0–3). In addition, the following parameters were assessed for severity: epithelial folding/distortion (0–2), goblet cell metaplasia (0–2), smooth muscle cell hypertrophy (0–2), and subepithelial fibrosis (0–2).

**Flow cytometry**

On day 14, BAL and a portion of the right lung lobe were collected and processed as previously described. To assess cellular infiltrate,
1 million cells of lung or BAL were analyzed using an Ab mixture against the following mouse Ags: Siglec-F (clone E50-2440), CD11b (clone M1/70), Ly-6G (clone IA8), CD11c (clone N418), CD45 (clone 30-F11), CD3 (clone 145-2C11), and B220 (clone RA3-6B2). All Abs were from BioLegend, eBioscience/Thermo Fisher Scientific, and BD Biosciences. The gating strategies were performed as follows. Lungs or BAL cells were gated for singlets. Of these, a forward scatter versus CD45 plot was used to further gate CD45+ cells. A plot of CD11c versus Siglec-F gated on CD45+ cells was used to discriminate alveolar macrophages (CD11c−Siglec-F+) from eosinophils (CD11c+ Siglec-F−). A plot of CD11b versus Ly-6G gated on CD45+ cells was used to identify neutrophils (CD11b+Ly-6G−). A plot of side scatter (SSC) versus CD3 and B220 gated on CD45+ cells was used to identify lymphocytes (CD3+ and B220+, SSClo). For intracellular cytokine staining, cell suspensions were obtained from lung tissue, stimulated with PMA (5 ng/ml) and ionomycin (500 ng/ml) in the presence of brefeldin A and monensin and stained for cell surface Ags and intracellular cytokines. For cell surface staining, Abs against mouse CD45 (clone 30-F11) and mouse CD4 (clone GK1.5) were used (BioLegend). The cells were then fixed and permeabilized using a fixation/permeabilization kit (BD Biosciences) and stained intracellularly using Abs against mouse IL-4 (clone 11B11), mouse IL-5 (clone TRFK5), mouse IL-17A (clone TC11-18H10.1), and mouse IFN-γ (clone XMG 1.2) (all from BioLegend). All samples were acquired using a Novoocyte flow cytometer (ACEA Biosciences, San Diego, CA) and analyzed using the NovoExpress Software.

**Lung homogenate cytokine analysis**

A portion of the right lobe of the lung was homogenized in T-PER buffer with protease inhibitors (Thermo Fisher Scientific, Waltham, MA). Samples were normalized to 0.5 mg/ml protein in LEGENDplex assay buffer (BioLegend, San Diego, CA) using a Bradford Assay (Bio-Rad Laboratories, Hercules, CA). A 13-plex bead-based immunoassay was performed using the manufacturer’s instructions (LEGENDplex Th Panel; BioLegend). All samples were acquired using Novocyte flow cytometer (ACEA Biosciences) and analyzed using the LEGENDplex Data Analysis software (v8; VigejneTech, Carlisle, MA). Using the provided standards, the analysis software automatically performs curve fitting and returns values for experimental samples only if these fall within the bounds of the standard curve generated (i.e., invalid samples do not return a value or are expressed by inequalities).

**Serum Ab analysis**

Mice were subjected to cardiac puncture for collection of blood, which was clotted for 30 min in serum separator tubes prior to centrifugation for 10 min at 4°C for collection of serum. Serum was diluted 1:10 in assay diluent. Murine anti-HDM IgG and IgG ELISA kits were obtained from Chondrex (Redmond, WA) and used as directed by the manufacturer. Assays were developed and analyzed as previously described (15).

**flexiVent analysis for AHR**

On day 28, mice were anesthetized using a mixture of ketamine/xylazine/acepromazine (65, 13, and 2 mg/kg, respectively). Once appropriate plane of anesthesia was achieved, mice were cannulated i.t. and connected to a flexiVent mechanical ventilator (SCRIEQ). Basal lung mechanics and AHR to increasing doses of inhaled aerosolized methacholine (0, 3.125, 6.25, 12.5, 25, 50, and 100 mg/ml) was measured using preset scripts. Deep Inflation, SnapShot-150, Quick Prime-3, and PVs-P perturbations were collected at baseline three times. For each dose, SnapShot-150 and Quick Prime-3 perturbations were collected 12 times. Analysis was conducted using the FlexiWare 7 Software (SCRIEQ).

**Statistical analysis**

Statistical analysis was conducted using GraphPad Prism. Significance levels were fixed at 5% for each measured response. Figure legends indicate specific tests used for analysis of each dataset, number of animals per group, and number of times the experiment was repeated. Bar heights indicate means, and error bars indicate SEM.

**RESULTS**

**Early inhibition of RIP2 reduces lung pathology in mice subjected to an acute HDM asthma model**

We have previously shown that genetic loss of RIP2 attenuates lung pathology in response to HDM exposure (15). In the prior study, we additionally had evidence to indicate that RIP2 was important in the HDM-induced proinflammatory chemokine release in the lung very early during exposure (within 24 h). Follow-up bone marrow chimera studies suggested that RIP2 in the nonhematopoietic compartment was important for mediating this effect (Supplemental Fig. 1). However, in the absence of conditional, inducible, or floxed RIP2 strains, we chose instead to investigate the role of RIP2 specifically during the early response to HDM through pharmacological inhibition. We subjected mice to an acute HDM model of asthma and provided a selective RIP2 inhibitor (GSK583) via chow at a dose of 30 mg/kg/d on the 5 d during and surrounding the initial exposure to HDM (days −2 to 2, Fig. 1A). This would allow us to distinguish early involvement of RIP2 within structural cells and APCs versus possible direct effects on adaptive immunity. The specificity, mechanism, and in vivo inhibitory activity of GSK583 have been previously reported elsewhere (23). On day 14 of this model, mice were euthanized, and lungs were harvested and fixed for histological examination. Paraffin-embedded sections were stained using H&E, PAS, or trichrome stains and then scored blindly. We used a combination of parameters to create an inflammatory index (maximum score of 16) comprised of individual scores for bronchoarterial inflammation, amuscular blood vessel inflammation, interalveolar space inflammation, pleural inflammation, and pulmonary vein inflammation. Early inhibition of RIP2 in GSK583-treated mice was sufficient to reduce overall inflammation compared with their vehicle-treated counterparts (Fig. 1B, with corresponding graph in Fig. 1C). Similarly, this early inhibition of RIP2 using GSK583 was
sufficient to reduce mucus production as seen with PAS staining (magenta in PAS stain in Fig. 1B, with corresponding graph in Fig. 1D) and collagen deposition as seen with trichrome staining (blue in trichrome stain in Fig. 1B, with corresponding graph in Fig. 1G) compared with vehicle-treated mice. In addition, GSK583-treated mice demonstrated reduced lumen narrowing (increased lumen area) (Fig. 1E) and decreased epithelial thickness (Fig. 1F) compared with vehicle-treated mice subjected to an acute HDM asthma model. Collectively, these data show that RIP2 inhibition using GSK583 during the initial exposure to HDM is sufficient to improve lung pathology in an acute HDM asthma model.

Early prophylactic inhibition of RIP2 reduces eosinophilia and lung neutrophilia in an HDM model of asthma

To assess the effect of early pharmacological inhibition of RIP2 in an HDM asthma model on the recruitment of inflammatory cells to the airway, we harvested BAL and lung cells and stained these using a panel of Abs that would allow discrimination of hematopoietic cells, lymphocytes, neutrophils, alveolar macrophages, and eosinophils when subjected to flow cytometric analysis. Fig. 2A shows that mice undergoing pharmacological inhibition of RIP2 during initial exposure to HDM allergen (GSK583-treated mice) have significantly reduced numbers of CD45+ cells and eosinophils recovered from the BAL (corresponding representative gating strategies shown in Fig. 2B). There was a trend for decreased numbers of lymphocytes and neutrophils recovered in the GSK583-treated BAL compared with vehicle-treated mice, although this difference was NS. Similar to the BAL, early inhibition of RIP2 led to significantly reduced numbers of CD45+ cells and eosinophils recruited to the lung compared with vehicle-treated mice (Fig. 2C, with corresponding representative gating strategies shown in Fig. 2D). Additionally, recruitment of
neutrophils were also significantly decreased in the lung (Fig. 2C, 2D). Overall, these results indicate that early inhibition of RIP2 can reduce eosinophilia and lung neutrophilia during an acute HDM asthma model.

**Early pharmacological inhibition of RIP2 downregulates Th2 and Th17 immunity in an acute HDM model of asthma**

The adaptive immune response during an HDM asthma model is largely Th2 and Th17 dominated. To assess the effects of early pharmacological inhibition of RIP2 on the resulting adaptive immune response, we collected lung cells at day 14 of the acute HDM asthma model, stimulated these with PMA + ionomycin, and performed intracellular cytokine staining to assess the production of Th1-, Th2-, or Th17-associated cytokines. We observed a reduction in Th2 (CD4+IL-4+IL-5+) cell numbers within the lung in GSK583-treated mice, which is consistent with the previously observed decrease in eosinophilia and neutrophilia, whereas Th1 (CD4+IFN-γ) cell numbers were NS altered (Fig. 3A). Corresponding representative gating strategies are shown in Fig. 3B.

Furthermore, we also assessed the effect of early and acute RIP2 inhibition on the production of HDM-specific Abs. We have previously shown that on the C57BL/6J background (without the use of an additional adjuvant such as alum), the HDM asthma model leads primarily to an increase in the production of HDM-specific total IgG and the Th2-associated IgG1 subclass of Abs (15). Changes in levels of these Abs in the serum of GSK583- or vehicle-treated mice suggested a trend toward decreased levels of HDM-specific total IgG and IgG1; however, this was not statistically significant (Fig. 3C).

To additionally examine the local adaptive immune response within the lung, we performed a bead-based multiplex assay with lung homogenates from GSK583- and vehicle-treated mice (Fig. 4). This assay measures cytokines collectively secreted by the major Th lineages (Th1, Th2, Th9, Th17, Th22, and T follicular cells). These data indicate that there was a significant reduction in the levels of IL-4 and IL-5 in the lungs of GSK583-treated mice compared with vehicle-treated mice on an HDM asthma model without appreciable alteration of any of the other 11 Th cytokines tested (Fig. 4). Collectively, these data indicate that pharmacological inhibition of RIP2 during the initial exposure to HDM is enough to decrease the numbers of Th2 and Th17 cells in the lung and to reduce the production of local Th2-derived cytokines.

**Early inhibition of RIP2 in mice undergoing a chronic HDM asthma model exhibits disparate effects on lung pathology and AHR**

Given that acute models of asthma do not recapitulate many important features of this chronic disease such as airway remodeling and AHR, we also wanted to use a chronic HDM asthma model to determine whether early pharmacological inhibition of RIP2 had beneficial effects that would still be evident even at the later stages of this disease. As such, we treated mice with GSK583 or vehicle chow for 5 d around the time of initial exposure to HDM allergen and continued to expose them to HDM for a period of 4 wk as depicted in Fig. 5A. On day 28 of the model, mice were euthanized, and lungs were harvested, fixed, paraffin embedded, and stained for histological examination. H&E, PAS, and trichrome staining was performed, and sections were scored by a blinded observer. Similar to the acute model, early inhibition of RIP2 using GSK583 was sufficient to reduce the total inflammatory index (Fig. 5B, with corresponding graph in Fig. 5C) and mucus production as shown by PAS positivity (magenta in PAS staining in Fig. 5B, with corresponding graph in Fig. 5E) compared with vehicle-treated mice when mice were subjected to a chronic HDM model. In addition to evaluating inflammation, we also assessed airway remodeling. Using a combination of parameters encompassing the severity and prevalence of epithelial folding/distortion, goblet cell metaplasia, smooth muscle cell hypertrophy, subepithelial fibrosis, peribronchial trichrome blue staining, and parenchymal trichrome blue staining, we report an airway remodeling index (maximum score of 22). Early inhibition of RIP2 using GSK583 exhibited significantly reduced airway remodeling compared with vehicle-treated mice (11.22 ± 0.88 compared with 21 ± 0.29) when mice were subjected to a chronic model of asthma (Fig. 5B, with corresponding graph in Fig. 5D). These results indicate that by several histological parameters, early inhibition of RIP2 is enough to improve lung pathology and airway remodeling, even during a chronic model of asthmatic disease.

In addition, we assessed whether treatment with GSK583 would lead to deficient HDM-specific Ab responses in the chronic HDM asthma model. Similar to the acute model, there was a trend for reduced HDM-specific total IgG and IgG1 Ab levels in GSK583-treated mice compared with vehicle-treated mice; however, this was NS (Fig. 5F).

Last, to determine whether pharmacological inhibition of RIP2 during initial exposure to allergen affected AHR, mice treated with either GSK583 or vehicle chow underwent a chronic HDM asthma model. On day 28, mice were anesthetized, cannulated, connected to the flexiVent ventilator, and subjected to various mechanical perturbations in a customized asthma challenge script that included administration of nebulized methacholine at increasing doses in between measurements. Resistance of the total respiratory system (Rrs), central airway Newtonian resistance (Rn), elastance of the respiratory system (Ers), tissue damping (Max G), and tissue elastance (Max H) were calculated for each mouse at each dose of methacholine. No significant changes in Rrs (Fig. 6A) or Rn (Fig. 6B) were observed with GSK583 treatment compared with vehicle treatment. Ers (Fig. 6C), Max G (Fig. 6D), and Max H (Fig. 6E) were slightly decreased in GSK583-treated mice compared with vehicle-treated mice at a the highest dose of MCh (100 mg/ml); however, these changes were NS. Overall, these results indicate that early inhibition of RIP2, although sufficient to reduce lung pathology and airway remodeling, is by itself not sufficient to decrease AHR in a chronic HDM asthma model.

**DISCUSSION**

Currently, the only disease-modifying treatment available for asthmatics is allergen immunotherapy (AIT) (24). AIT has a long
FIGURE 2. Early prophylactic inhibition of RIP2 reduces eosinophilia and lung neutrophilia in an acute HDM model of asthma.

Wild-type C57BL/6 mice were subjected to an acute HDM asthma model and were administered either regular chow or chow containing RIP2 inhibitor (GSK583), as indicated in Fig. 1A. On day 14, mice were euthanized, and BAL cells or dissociated lung cells were isolated, stained for immune cell markers, and subjected to flow cytometric analysis. (A) The total number of each cellular population within the BAL for vehicle- compared with GSK583-treated mice. (B) Flow cytometry gating strategy for obtaining BAL cell counts in (A). (C) The numbers of each cellular population within a
history of efficacy primarily in the form of s.c. immunotherapy (or “allergy shots”) and, more recently, as sublingual formulations. The proposed mechanisms for the effectiveness of AIT include induction of T cell anergy, induction of regulatory T cells, or immune deviation (25). The result is the production of Abs of the IgG4 or IgG isotype with the ability to block allergen-specific IgE.

Although this treatment has been available for some time, it is generally underused because of lack of standardization (allergen preparation, potency, delivery system, and route of delivery) and is contraindicated for patients with uncontrolled asthma (25). In contrast, current pharmacotherapeutic approaches, although safe and effective, are only capable of managing the allergic asthmatic symptoms. This would mean that maintaining the efficacy would require continuous administration. Ideally, an emerging therapy for allergic asthma would have the lasting, disease-modifying efficacy of AIT with the ease and safety of pharmacotherapeutic

---

**FIGURE 3.** Pharmacological inhibition of RIP2 downregulates Th2 and Th17 immunity in an HDM model of asthma.

Wild-type C57BL/6 mice were subjected to an acute HDM asthma model and were administered either regular chow or chow containing RIP2 inhibitor (GSK583), as indicated in Fig. 1A. On day 14, mice were euthanized, and dissociated lung cells were stimulated with PMA and ionomycin and subjected to intracellular cytokine staining. (A) The numbers of CD4⁺IFN-γ⁺ (Th1), CD4⁺IL-17⁺ (Th17), or CD4⁺IL-4⁺IL-5⁺ (Th2) within a standardized amount of lung tissue are shown for vehicle- compared with GSK583-treated mice. (B) Flow cytometry gating strategy for intracellular cytokine staining cell numbers shown in (A). (C) Levels of HDM-specific total IgG and IgG1 Abs in the serum of vehicle chow- or RIP2 inhibitor (GSK583) chow- treated mice subjected to an acute HDM asthma model as measured by ELISA. Data are presented as scatter plots with bars in which bar heights represent means ± SEM. Filled-in circles represent individual data points for vehicle/control chow-treated mice, and open circles represent individual data points for GSK583-treated mice. Data are pooled from three independent experiments for a total of n = 9 mice per group. Statistical analysis was performed using an unpaired, two-tailed Student t test. *p < 0.05.

---

https://doi.org/10.4049/immunohorizons.2000073
approximate. The capacity for AIT to induce long-lived effects relies on its ability to modulate or reprogram adaptive immunity by affecting upstream cues such as the generation of a regulatory or immature DC phenotype. In the current study, we sought to determine whether interfering with early upstream inflammatory cues, such as those emanating from activation of the kinase RIP2, would be capable of modulating the immune response with lasting effects.

Our previous study using RIP2 KO mice in the context of an HDM model of allergic asthma identified RIP2 as a kinase important in promoting not only the Th2 and Th17 response to HDM but also the accompanying airway eosinophilia and lung pathology (15). RIP2 is widely expressed in various innate immune populations such as neutrophils, macrophages, and DCs, where it serves important functions in mediating host defense. Some reports also indicate a role for RIP2 within T cells (26, 27). Additionally, expression and function of RIP2 as well as its upstream receptor NOD2 has been demonstrated within nonhematopoietic cells such as airway epithelial cells (28). We suspected that involvement of RIP2 was crucial during the very early stages of allergic sensitization and likely to be primarily acting within airway epithelial cells because loss of RIP2 inhibited the early HDM-induced proinflammatory chemokine response in the lung and in primary airway epithelial cells without influencing ILC2 expansion (15). Subsequent bone marrow chimera experiments confirmed the importance of RIP2 within the nonhematopoietic compartment in mediating these early responses. In our previous studies, RIP2 was absent throughout the asthma model (global RIP2 KO), and early effects of RIP2 within innate or structural cells could not be distinguished from any potential late effects on adaptive immunity. In the absence of any inducible and conditional RIP2 mouse strains that would allow us to tease apart these roles, in the current study, we decided to intervene using pharmacological means. Using GSK583, a specific RIP2 inhibitor, we were able to verify and isolate the importance of RIP2 during the initial period, leading to the establishment of T cell immunity by inactivating RIP2 during a crucial window.

**FIGURE 4. Early in vivo inhibition of RIP2 reduces Th2-associated cytokines in the lung.**

Wild-type C57BL/6 mice were subjected to an acute HDM asthma model and were administered either regular chow or chow containing RIP2 inhibitor (GSK583), as indicated in Fig. 1A. On day 14, mice were euthanized, and lung tissue was collected and lysed in protein extraction buffer containing inhibitors. Supernatants were subjected to multiplexed bead-based immunoassay for measurement of various Th-associated cytokines. Data are presented as scatter plots with bars in which bar heights represent means ± SEM. Filled-in circles represent individual data points for vehicle/control chow–treated mice, and open circles represent individual data points for GSK583–treated mice. Data are pooled from three independent experiments for a total of n = 8–9 mice per group (outlier by Grubb test was excluded). Statistical analysis was performed using an unpaired, two-tailed Student t test. *p < 0.05.
We demonstrate that early acute inhibition of RIP2 is beneficial and immune modulating and that the effects on cellular inflammation and lung pathology (airway remodeling) persist long after treatment is discontinued. Although the lack of efficacy of RIP2 inhibition on AHR is somewhat disappointing (no change in Rn), the trend in the reduction of Max G and Max H are suggestive for a potential role of RIP2 in influencing localized peripheral effects in the lung tissue, changes that may be more apparent if using a different genetic background, sensitization procedure (alum adjuvanted), or timing of inhibitor administration.

The duration of RIP2 inhibition (during and up to 2 d after initial allergen exposure) will have most likely impacted airway structural cells, APC, and ILC2 cells within the lung. Although ILC2 numbers increase in the setting of HDM asthma, our previous studies did not find any differences in ILC2 frequencies in the absence of RIP2, and therefore, we suspect that involvement of this cell type in the observed reduction in Th2 and Th17 responses is unlikely. We have previously reported a role for RIP2 in airway epithelial cell–derived production of CCL2/MCP-1, a chemokine that has been shown by others to be important in DC recruitment into the lung (29–31) and in establishing a Th2-promoting milieu (32). In DCs, activation of NOD2:RIP2 in synergy with activation of other TLRs has been demonstrated to promote production of IL23p19, IL-1α, IL-1β, and Th17 immunity (33). Thus, a possible model is that during the early period of allergic sensitization to

---

**FIGURE 5.** Mice undergoing a chronic HDM asthma model exhibit improved lung pathology with early RIP2 inhibition but minimal effects on HDM-specific Ab responses.

(A) Wild-type C57BL/6 mice were subjected to a chronic HDM asthma model and were administered either regular chow or chow containing RIP2 inhibitor (GSK583 at 30 mg/kg/d) for the 5 d during and surrounding the initial exposure to HDM (red arrows). On day 28, mice were euthanized, and lungs were harvested, fixed in 10% formalin, and embedded in paraffin. (B) Consecutive sections were stained with either H&E, PAS, or trichrome. Severity of lung pathology was blindly scored based on (C) inflammatory index, (D) remodeling index, and (E) mucus production. (F) Levels of HDM-specific total IgG and IgG1 Abs in the serum of vehicle chow–or RIP2 inhibitor (GSK583) chow–treated mice subjected to a chronic HDM asthma model as measured by ELISA. Data are presented as scatter plots with bars in which bar heights represent means ± SEM. Filled-in circles represent individual data points for vehicle/control chow–treated mice, and open circles represent individual data points for GSK583–treated mice. Data are pooled from three independent experiments for a total of n = 9 mice per group. Statistical analysis was performed using an unpaired, two-tailed Student t test. ***p < 0.001, ****p < 0.0001.
HDM, RIP2 acts within airway epithelial cells to promote recruitment of DCs and support polarization of Th2 immunity and within DCs to promote Th17 immunity. Consequently, interfering with these early signals leads to a reduction in Th2 and Th17 numbers, a decrease in eosinophilia, lung neutrophilia, and an improvement in the histological parameters of inflammation.

One of the limitations of these studies is that we did not assess the therapeutic efficacy of RIP2 inhibition. This was intentional as we wanted to confirm the importance of RIP2 activity during the early response to HDM, which we demonstrate influences the later establishment of adaptive immunity and allows for a sustained decrease in airway inflammation and a protective effect on airway remodeling. How early RIP2 inhibition promotes sustained immune modulation is currently unknown. We did not assess the generation of tolerogenic DCs or regulatory T cells in this study, which could be responsible for the protective effects in the face of repeated allergen exposure. However, data arguing against this mechanism include no significant differences observed in local IL-10 production within the lung and that RIP2 (at least downstream of NOD2 engagement) has been shown to be important for IL-10 production (in direct opposition of this hypothesis) (34, 35). We cannot rule out that RIP2 inhibition may have directly or indirectly influenced other phenotypes of DCs by affecting the production of secreted regulatory molecules, such as retinoic acid, TGF-β, and IDO, or expression of cell surface markers important for polarization to Th2 immunity (OX40L, Jagged 2, etc.) or influencing DC migration. These would be interesting avenues to pursue in the future to identify important cellular mechanisms for the observed sustained efficacy of early RIP2 inhibition.

In practicality, it would be difficult to capture the period at which sensitization to allergens occurs. Given our model above, how would therapeutic targeting of RIP2 potentially work in a sensitized individual (an established model of allergic asthma)? Subsequent allergen exposure also results in reactivation of the airway epithelium and production of various chemokines that result in an influx of DCs important in restimulation of memory T cell responses. Thus, RIP2 inhibition may still be beneficial in preventing DC recruitment and memory T cell reactivation and potentially promote immune modulation or deviation. However, this direction should also be approached cautiously as RIP2 has also been described to play a T cell–intrinsic role (regulating pathogenic Th17 immunity in certain models of inflammation). We suspect that although a similar benefit in attenuation of allergic airway inflammation and Th2 immunity may be observed when RIP2 inhibitors are administered therapeutically, whether such therapies also increase pathogenic Th17 responses remains to be seen. Given the widespread expression and importance of RIP2 in airway inflammation and Th2 immunity, it would be very appealing. A short therapeutic regimen would additionally reduce any potential concerns about immunosuppression given the fact that RIP2 does carry out many host protective functions. As a potential therapeutic target, RIP2 has garnered a great deal of interest as beneficial effects of genetic loss or pharmacological inhibition of this kinase has been

**FIGURE 6.** GSK583-treated mice did not exhibit changes in HDM-induced AHR.

Wild-type C57BL/6 mice were subjected to a chronic HDM asthma model and were administered either regular chow or chow containing RIP2 inhibitor (GSK583), as indicated in Fig. 5A. On day 28, mice were anesthetized, i.t. cannulated, and connected to a flexiVent mechanical ventilator. Baseline lung function was obtained, after which mice were subjected to increasing doses of methacholine to measure AHR. Dose-dependent changes in (A) Rrs, (B) Rn, (C) Ers, (D) Max G, and (E) Max H are shown. Lines connected by filled-in circles represent vehicle/control chow–treated mice, and lines connected by open circles represent individual data points for GSK583–treated mice. Data are pooled from two independent experiments for a total of n = 5–6 mice per group. The area under the curve was calculated for each treatment, and an unpaired, two-tailed Student t test was performed comparing the two.
demonstrated in models of inflammatory bowel disease (19, 36), ex vivo sarcoidosis tissues (37), multiple sclerosis (18, 38), and various cancers (39, 40). This work is the first to demonstrate the efficacy and modulatory activity of a RIP2-targeting compound using a clinically relevant model of allergic asthma. Numerous inhibitors have both been discovered and developed for modulation of RIP2 activity (23, 41–49). The RIP2 inhibitor used in this study, GSK583, has been reported to be highly selective and exhibits strong potency even in vivo (23, 45). Numerous reports have emerged recently regarding the mechanism of action of such inhibitors in attenuating the downstream inflammatory signaling emanating from RIP2. Although many RIP2-targeted therapies strongly inhibit the kinase function of RIP2, the ability of RIP2 to bind XIAP and undergo ubiquitination rather than its kinase activity per se appears to be crucial for propagation of NOD2 inflammatory signaling (45, 46). GSK583 has been demonstrated to disrupt XIAP: RIP2 binding and prevent RIP2 ubiquitination, and optimized derivatives of this compound (GSK2983559) briefly entered into human clinical trials in 2017 (21). However, this trial was terminated in 2019 because of “nonclinical toxicology findings and reduced safety margins” (21). The data presented in this current study demonstrating a clear benefit of acute and early RIP2 inhibition for attenuation of allergic asthma and modulation of Th2 immunity will hopefully provide the needed rationale and support for continued development of what will likely be very useful compounds for asthma and other inflammatory diseases.

DISCLOSURES

The authors have no financial conflicts of interest.

ACKNOWLEDGMENTS

We thank Pamela Haile, Bart Votta, Allison Beal, and John Lich for their assistance in selection of the GSK583 RIP2 inhibitor, determination of the appropriate dose in chow, and providing the compound for use in this study. We additionally thank them for helpful comments during revision of the manuscript. We thank UCF Core facilities for use of the gentleMACS tissue dissociator and Madelyn’s thesis committee for discussions regarding work.

REFERENCES

INHIBITION OF RIP2 ATTENUATES ALLERGIC ASTHMA


